18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: A meta-analysis

Journal of the National Cancer Institute

Volumn 100, Issue 10, 2008, Pages 712-720

  Kyzas, Panayiotis A ^a,b   Evangelou, Evangelos ^a   Denaxa Kyza, Despina ^a   Ioannidis, John P A ^a,c,d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ASPIRATION BIOPSY; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; CANCER STAGING; CONFIDENCE INTERVAL; HEAD AND NECK TUMOR; LYMPH NODE; META ANALYSIS; METHODOLOGY; NECK; PATHOLOGY; PREDICTION AND FORECASTING; ROC CURVE; SCINTISCANNING;

CONFIDENCE INTERVALS; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NECK; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 44449118981     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn125     Document Type: Article

References (62)

1. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 1994;120(7):699-702.
2. Snow GB, Patel P, Leemans CR, Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol. 1992;249(4):187-194.
3. Ferlito A, Rinaldo A, Robbins KT, et al. Changing concepts in the surgical management of the cervical node metastasis. Oral Oncol. 2003;39(3):429-435.
4. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. Head Neck Surg. 1988;10(3):160-167.
5. Castelijns JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol. 2002;12(4):727-738.
6. Castelijns JA, van den Brekel MW. Detection of lymph node metastases in the neck: radiologic criteria. AJNR Am J Neuroradiol. 2001;22(1):3-4.
7. Hao SP, Ng SH. Magnetic resonance imaging versus clinical palpation in evaluating cervical metastasis from head and neck cancer. Otolaryngol Head Neck Surg. 2000;123(3):324-327.
8. Stern WB, Silver CE, Zeifer BA, Persky MS, Heller KS. Computed tomography of the clinically negative neck. Head Neck. 1990;12(2):109-113.
9. Feinmesser R, Freeman JL, Feinmesser M, Noyek A, Mullen JB. Role of modern imaging in decision-making for elective neck dissection. Head Neck. 1992;14(3):173-176.
10. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol. 1992;158(5):961-969.
11. Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology. 1998;207(1):123-130.
12. Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003;44(5):717-724.
13. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46(6):958-963.
14. Lee JC, Kim JS, Lee JH, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007;43(7):686-692.
15. Dietl B, Marienhagen J, Kuhnel T, Schreyer A, Kolbl O. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective [published online ahead of print September 6, 2007]. Oral Oncol. doi:10.1016/j.oraloncology.2007.06.014.
16. Robbins KT, Clayman G, Levine PA, et al. American Head and Neck Society, American Academy of Otolaryngology - Head and Neck Surgery. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002;128(7):751-758.
17. Rutter CM, Gatsonis CA. A hierarchical regression approach to metaanalysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865-2884.
18. Pohar S, Brown R, Newman N, Koniarczyk M, Hsu J, Feiglin D. What does PET imaging add to conventional staging of head and neck cancer patients? [published online ahead of print March 26, 2007]. Int J Radiat Oncol Biol Phys. 2007;68(2):383-387. doi:10.1016/j.ijrobp.2006.12.044.
19. Roh JL, Ryu CH, Kim JS, et al. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer [published online ahead of print November 16, 2006]. Oral Oncol. 2007;43(8):757-763. doi:10.1016/j.oraloncology.2006.09.004.
20. Krabbe CA, Dijkstra PU, Pruim J, et al. FDG PET in oral and oropharyngeal cancer. Value for confirmation of N0 neck and detection of occult metastases [published online ahead of print February 14, 2007]. Oral Oncol. 2008;44(1):31-36. doi:10.1016/j.oraloncology.2006.12.003.
21. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48(5):726-735.
22. Schoder H, Carlson DL, Kraus DH, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med. 2006;47(5):755-762.
23. Jeong HS, Baek CH, Son YI, et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck. 2007;29(3):203-210.
24. Hafidh MA, Lacy PD, Hughes JP, Duffy G, Timon CV. Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas [published online ahead of print May 25, 2006]. Eur Arch Otorhinolaryngol. 2006;263(9):853-859. doi:10.1016/j.amjoto.2006.03. 004.
25. Wensing BM, Vogel WV, Marres HA, et al. FDG-PET in the clinically negative neck in oral squamous cell carcinoma [erratum in Laryngoscope. 2006;116(7 Pt 1):1302]. Laryngoscope. 2006;116(5):809-813.
26. Ke Z, Liu M, Liu Y, He Z, Zhang Y, Zhang W. Diagnostic value of 18F-fDG Pet/CT in the detection of the cervical lymph nodes metastasis [in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006;20(6):243-245.
27. Ng SH, Yen TC, Chang JT, et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24(27):4371-4376.
28. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(1):129-136.
29. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2- fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. 2005;115(7):1186-1190.
30. Jones J, Farag I, Hain SF, McGurk M. Positron emission tomography (PET) in the management of oro-pharyngeal cancer. Eur J Surg Oncol. 2005;31(2):170-176.
31. Brouwer J, de Bree R, Comans EF, Castelijns JA, Hoekstra OS, Leemans CR. Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior? [published online ahead of print December 17, 2003]. Eur Arch Otorhinolaryngol. 2004;261(9):479-483. doi:10.1007/s00405-003-0727-3.
32. Bruschini P, Giorgetti A, Bruschini L, et al. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT. Acta Otorhinolaryngol Ital. 2003;23(6):446-453.
33. Wax MK, Myers LL, Gona JM, Husain SS, Nabi HA. The role of positron emission tomography in the evaluation of the N-positive neck. Otolaryngol Head Neck Surg. 2003;129(3):163-167.
34. Popperl G, Lang S, Dagdelen O, Jager L, Tiling R, Hahn K. Tatsch K. Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer [in German]. Rofo. 2002;174(6):714-720.
35. Hlawitschka M, Neise E, Bredow J, et al. FDG-PET in the pretherapeutic evaluation of primary squamous cell carcinoma of the oral cavity and the involvement of cervical lymph nodes. Mol Imaging Biol. 2002;4(1):91-98.
36. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg. 2002;236(2):208-217.
37. Hyde NC, Prvulovich E, Newman L, Waddington WA, Visvikis D, Ell P. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol. 2003;39(4):350-360.
38. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med. 2001;28(7):816-821.
39. Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg. 2000;231(2):229-234.
40. Stuckensen T, Kovacs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg. 2000;28(6):319-324.
41. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin. 1999;38(8):312-318.
42. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg. 1999;125(12):1322-1328.
43. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope. 1999;109(6):880-885.
44. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25(9):1255-1260.
45. Paulus P, Sambon A, Vivegnis D, et al. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope. 1998;108(10):1578-1583.
46. Myers LL, Wax MK, Nabi H, Simpson GT, Lamonica D. Positron emission tomography in the evaluation of the N0 neck. Laryngoscope. 1998;108(2):232-236.
47. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci. 1997;22(3):209-214.
48. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med. 1995;36(10):1747-1757.
49. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med. 1995;36(2):211-216.
50. McGuirt WF, Williams DW III, Keyes JW Jr, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope. 1995;105(4 Pt1):373-375.
51. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer. 1994;73(12):3047-3058.
52. Moya F, Gomez F, De Pedro M, et al. Utility of metabolic imaging in oral squamous cell carcinoma (SCC) staging. Experience in 30 Patients. Clin Positron Imaging. 2000;3(4):171.
53. Ferlito A, Rinaldo A, Silver CE, et al. Elective and therapeutic selective neck dissection [published online ahead of print June 23, 2005]. Oral Oncol. 2006;42(1):14-25. doi:10.1016/j.oraloncology.2005.03.009.
54. Wei WI, Ferlito A, Rinaldo A, et al. Management of the N0 neck - reference or preference [published online ahead of print June 24, 2005]. Oral Oncol. 2006;42(2):115-122. doi:10.1016/j.oraloncology.2005.04.006.
55. Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck. 1999;21(6):517-525.
56. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174(4):469-476.
57. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97(14):1043-1055.
58. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99(3):236-243.
59. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: an empirical assessment. PLoS Med. 2007;4(3):e79.
60. Ioannidis JP. Why most published research findings are false [published online ahead of print August 30, 2005]. PLoS Med. 2005;2(8):e124. doi:10.1371/journal.pmed.0020124.
61. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results [published online ahead of print November 5, 2007]. Eur J Cancer. 2007;43(17):2559-2579. doi:10.1016/j.ejca.2007.08.030.
62. Pimenta Amaral TM, Da Silva Freire AR, Carvalho AL, Pinto CA, Kowalski LP. Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth. Oral Oncol. 2004;40(8):780-786.